Co-Administration of Inhibitors of HDAC6 and SGLT2 in Murine HFpEF Models Results in Additive Improvements in Cardiac Structural and Functional Measures

HFpEF is a form of heart failure characterized by diastolic dysfunction and associated with high morbidity, mortality and significant unmet need. Previously, we have demonstrated that selective inhibition of histone deacetylase 6 (HDAC6) has positive effects on diastolic dysfunction and left ventricular thickness of the heart, as well as overall improvements in systemic inflammation and metabolism, in a mouse model of HFpEF using a high-fat diet (HFD) and L-NAME. Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor approved by the FDA for HFpEF patients, works as expected in this model, confirming the potential clinical translatability of results seen with HDAC6 inhibitors.

Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Farshad Farshidfar, Aliya Zeng, Reva Shenwai, Matthew Kozubov, Iris Wu, Sara Ranjbarvaziri, Amara Greer-Short, Anastasiia Budan, Emma Xu, Cindy Li, Melissa Van Pell, Charles Mackay, Xiaomei Song, James Priest, Gretchen Argast, Jin Yang, Timothy Hoey Tags: 104 Source Type: research